home
about us
science
pipeline
newsroom
contact
menu
Jun 25, 2024
Exeliom Biosciences collaborates with REMIND in MAINTAIN POP studyExplore
Apr 11, 2024
Exeliom Biosciences announces three phase II clinical trials in immuno-oncology with lead candidate combined with immune checkpoint inhibitors
Explore
Mar 4, 2024
Exeliom is awarded a $500k grant from the Crohn's and Colitis Foundation! 
Explore
#HealthcareInnovation #ClinicalTrial #CDI #Partnership #ExeliomBiosciences #HospicesCivilsdeLyon #MedicalResearch #HealthcareInnovation #ExeliomBiosciences #Biotech #Start-up #Microbiome #Cdiff
Nov 6, 2023
Exeliom Biosciences and Hospices Civils de Lyon announce clinical collaboration in recurrent Clostridioides difficile infection
Explore
#biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics
Oct 19, 2023
Exeliom Biosciences Announces that the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 1 Clinical Trial of EXL01 in Crohn’s Disease
Explore
#Faecalibacterium #GutHealth #HealthResearch #Microbiome #Biotherapeutics #Biotech
Sep 21, 2023
New review on Faecalibacterium published in FEMS Microbiology Reviews explores its potential for human health
Explore
#funding #SeriesA #Clinicaltrials
Jun 30, 2023
Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million ($26 Million) to Progress the Clinical Development of its Lead Candidate in Immuno-Oncology and Infectious Diseases.
Explore
Apr 27, 2023
SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Explore
Mar 21, 2023
Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease
Explore
Clinical Trial Live Biotherapeutics Crohn's Disease Belgium
Feb 24, 2022
Exeliom Biosciences announces approval of Clinical Trial Application from the Belgian Agency for Single Strain Live Biotherapeutic EXL01 (Faecalibacterium prausnitzii) for the treatment of Crohn’s Disease
Explore
Manufacturing
May 7, 2021
Exeliom Biosciences opens pilot manufacturing unit for Live Biotherapeutics (LBPs) thanks to European H2020 Accelerator Program
Explore
H2020 Accelerator Program Live Biotherapeutics Manufacturing
Aug 3, 2020
Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council
Explore
Deeptech Bpifrance Microbiome
Aug 12, 2019
Exeliom Biosciences is awarded 1.8M€ DeepTech grant from Bpifrance to advance its lead program
Explore
Nextbiotix Exeliom Biosciences
Feb 15, 2019
Nextbiotix becomes Exeliom Biosciences
Explore
I-lab2018 Bpifrance
Jul 23, 2018
Exeliom Biosciences is awarded I-Lab2018 from Bpifrance
Explore
Series-A Biotech Exeliom Biosciences Nextbiotix
Jul 5, 2018
Exeliom Biosciences (formerly Nextbiotix) raises €7 million to tackle inflammatory bowel diseases
Explore
Wilco
Sep 27, 2017
Exeliom Biosciences joins Wilco Incubator
Explore
Paris Biotech Santé
Sep 25, 2017
Exeliom Biosciences joins Paris Biotech Santé Incubator
Explore

newsroom

upcoming events

Discover

contact

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.